Facebook
Twitterhttps://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The global COVID-19 treatment market, valued at USD 59.2 million in 2025, is projected to reach USD 329.1 million by 2033, exhibiting a CAGR of 25.1% during the forecast period. The significant growth can be attributed to the rising prevalence of COVID-19, increasing government initiatives, and ongoing research and development activities in the development of novel treatments. Additionally, the growing demand for antiviral drugs and monoclonal antibodies, as well as supportive therapies, is further fueling market growth. The market is highly competitive, with prominent players such as Cadila Healthcare, Johnson & Johnson, ImmunoPrecise, Novartis, AstraZeneca, Cipla, AbbVie, Bayer, Regeneron Pharmaceuticals, Ascletis Pharma, GlaxoSmithKline, Gilead Sciences, Pharmstandard, Fujifilm Holdings, Zhejiang Hisun Pharmaceutical Co. Ltd, Roche, Sanofi, and Pfizer holding significant market shares. These companies are engaged in extensive research and development, strategic collaborations, and acquisitions to maintain their competitive positions. Moreover, the emergence of biosimilars and the potential availability of generic versions of COVID-19 treatments are expected to intensify competition in the market.
Facebook
TwitterThese documents record the equality analysis undertaken for the decision to move England into step 4 through the Health Protection (Coronavirus, Restrictions) (Steps etc.) (England) (Revocation and Amendment) Regulations 2021.
Ministers are required under the https://www.legislation.gov.uk/uksi/2011/2260/contents/made">Public Sector Equality Duty (PSED) as set out in section 149 of the Equality Act 2010 to have regard to the need to:
Ministers are required to consider the impact of policy decisions on people’s protected characteristics, with particular emphasis on meeting the duties set out above. These protected characteristics are:
The regulations covered by these PSED documents relate to the decision to move England into step 4 on 19 July 2021. This resulted in most legal restrictions, including those relating to social distancing and social contact, ending. All remaining businesses were allowed to reopen.
Facebook
Twitterhttps://www.promarketreports.com/privacy-policyhttps://www.promarketreports.com/privacy-policy
The size of the COVID 19 Diagnostics Market was valued at USD 81 billion in 2023 and is projected to reach USD 139.18 billion by 2032, with an expected CAGR of 8.04% during the forecast period. Recent developments include: May 2020 Bio-Rad Laboratories, Inc. Bio-Rad received FDA Emergency Use Authorization (EUA) for Droplet Digital PCR SARS-CoV-2 Test Kit for the detection of COVID-19., May 2020 F. Hoffmann-La Roche Ltd Roche received emergency use authorization (EUA) from the US FDA for the Elecsys Anti-SARS-CoV-2 antibody test for the detection of COVID-19., April 2020 Becton, Dickinson, and Company received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It uses in diagnosing the patients infected with COVID-19.. Key drivers for this market are: INCREASING NUMBER OF COVID-19 CASES 26, GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26; RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26; DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27. Potential restraints include: RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28, ACCURACY OF TEST RESULTS 28. Notable trends are: Rising prevalence of coronavirus disease.
Facebook
TwitterOur statistical practice is regulated by the Office for Statistics Regulation (OSR). OSR sets the standards of trustworthiness, quality and value in the Code of Practice for Statistics that all producers of official statistics should adhere to. You are welcome to contact us directly by emailing us with any comments about how we meet these standards.
These are the final statistics on road collisions and casualties for Great Britain in 2023.
Between 2022 and 2023, there was a small decline in reported road casualties in Great Britain with casualty numbers broadly following the trends observed before the COVID-19 pandemic. The number of fatalities in 2023 is the lowest recorded outside of years affected by the COVID-19 pandemic, although fatality figures are relatively small and can fluctuate from year to year. Overall casualties have returned to the steady decline observed prior to the COVID-19 pandemic, though the number of killed or seriously injured casualties has fallen less, particularly since 2017.
In reported road collisions in Great Britain in 2023, there were an estimated:
Alongside the main publication and full set of detailed road safety statistical tables, we have also published a range of road safety factsheets focussed on specific road users or topics, including the official statistics on e-scooter collisions and casualties, and new analyses looking at the ‘fatal 4’ factors based on the new road safety factors classification, and self-reported driver behaviour based on Crime Survey for England and Wales data.
We have also published an update on progress in implementing the latest STATS19 review and future development roadmap, as well as new tools to download and to map casualty data.
The next reported road casualty statistics, for the year to end June 2024, are scheduled for publication in November.
Road safety statistics
Email mailto:roadacc.stats@dft.gov.uk">roadacc.stats@dft.gov.uk
To hear more about DfT statistical publications as they are released, follow us on X at https://x.com/dftstats?lang=en">DfTstats.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
Facebook
Twitterhttps://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The global COVID-19 treatment market, valued at USD 59.2 million in 2025, is projected to reach USD 329.1 million by 2033, exhibiting a CAGR of 25.1% during the forecast period. The significant growth can be attributed to the rising prevalence of COVID-19, increasing government initiatives, and ongoing research and development activities in the development of novel treatments. Additionally, the growing demand for antiviral drugs and monoclonal antibodies, as well as supportive therapies, is further fueling market growth. The market is highly competitive, with prominent players such as Cadila Healthcare, Johnson & Johnson, ImmunoPrecise, Novartis, AstraZeneca, Cipla, AbbVie, Bayer, Regeneron Pharmaceuticals, Ascletis Pharma, GlaxoSmithKline, Gilead Sciences, Pharmstandard, Fujifilm Holdings, Zhejiang Hisun Pharmaceutical Co. Ltd, Roche, Sanofi, and Pfizer holding significant market shares. These companies are engaged in extensive research and development, strategic collaborations, and acquisitions to maintain their competitive positions. Moreover, the emergence of biosimilars and the potential availability of generic versions of COVID-19 treatments are expected to intensify competition in the market.